Licensing Long-Term Care Facilities Pharmacokinetics 
The Pharma Data
APRIL 14, 2021
A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987 ) is also ongoing. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity.
The Pharma Data
APRIL 16, 2021
A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987 ) is also ongoing. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
MAY 4, 2021
About OLUMIANT ® (baricitinib) OLUMIANT, a once-daily, oral JAK inhibitor was discovered by Incyte and licensed to Lilly. A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987 ) is also ongoing.
The Pharma Data
JANUARY 26, 2021
BLAZE-4 Additionally, initial results from the ongoing BLAZE-4 trial provide viral load and pharmacodynamic/pharmacokinetic data which demonstrated lower doses, including bamlanivimab 700 mg and etesevimab 1400 mg together, are similar to bamlanivimab 2800 mg and etesevimab 2800 mg together.
The Pharma Data
MARCH 5, 2021
A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987 ) is also ongoing. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity.
The Pharma Data
MARCH 11, 2021
A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987 ) is also ongoing. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity.
Expert insights. Personalized for you.
52 
Let's personalize your content